Suxamethonium
Suxamethonium (succinylcholine) is a depolarizing neuromuscular blocking agent that mimics acetylcholine at the neuromuscular junction nicotinic receptors, causing initial fasciculations followed by sustained depolarization and flaccid skeletal muscle paralysis used for rapid sequence induction and tracheal intubation. Its rapid onset of action (30-60 seconds) and short duration (10-15 minutes due to plasma cholinesterase hydrolysis) make it uniquely suited for emergency airway management. It carries risks of hyperkalemic cardiac arrest in patients with denervation injuries, burns, or prolonged immobility.
Peso Molecular
290,4000 g/mol
LogP
0,60
TPSA
52,60 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
InChI
InChI=1S/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
Molecular Formula
C14H30N2O4+2
HBD / HBA
- / 4
Ligações Rotacionáveis
11
Átomos Pesados
20
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Suxamethonium (succinylcholine) is a depolarizing neuromuscular blocking agent that mimics acetylcholine at the neuromuscular junction nicotinic receptors, causing initial fasciculations followed by sustained depolarization and flaccid skeletal muscle paralysis used for rapid sequence induction and tracheal intubation. Its rapid onset of action (30-60 seconds) and short duration (10-15 minutes due to plasma cholinesterase hydrolysis) make it uniquely suited for emergency airway management. It carries risks of hyperkalemic cardiac arrest in patients with denervation injuries, burns, or prolonged immobility.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Suxamethonium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL703. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5314. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="suxamethonium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/suxamethonium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/suxamethonium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/suxamethonium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="suxamethonium"></drugfyi-drug>